145 related articles for article (PubMed ID: 28120417)
1. PD-1 expression by canine T cells and functional effects of PD-1 blockade.
Coy J; Caldwell A; Chow L; Guth A; Dow S
Vet Comp Oncol; 2017 Dec; 15(4):1487-1502. PubMed ID: 28120417
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
Maekawa N; Konnai S; Ikebuchi R; Okagawa T; Adachi M; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Murata S; Ohashi K
PLoS One; 2014; 9(6):e98415. PubMed ID: 24915569
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockage delays murine squamous cell carcinoma development.
Belai EB; de Oliveira CE; Gasparoto TH; Ramos RN; Torres SA; Garlet GP; Cavassani KA; Silva JS; Campanelli AP
Carcinogenesis; 2014 Feb; 35(2):424-31. PubMed ID: 24031027
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients.
Pinard CJ; Stegelmeier AA; Bridle BW; Mutsaers AJ; Wood RD; Wood GA; Woods JP; Hocker SE
Vet Comp Oncol; 2022 Jun; 20(2):427-436. PubMed ID: 34797014
[TBL] [Abstract][Full Text] [Related]
8. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis.
Che YM; Zhang Y; Li M; Li XP; Zhang LL
J Cell Biochem; 2018 Apr; 119(4):3044-3057. PubMed ID: 29058791
[TBL] [Abstract][Full Text] [Related]
10. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
11. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer.
Saito H; Kuroda H; Matsunaga T; Osaki T; Ikeguchi M
J Surg Oncol; 2013 Apr; 107(5):517-22. PubMed ID: 23129549
[TBL] [Abstract][Full Text] [Related]
12. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
Choi JW; Withers SS; Chang H; Spanier JA; De La Trinidad VL; Panesar H; Fife BT; Sciammas R; Sparger EE; Moore PF; Kent MS; Rebhun RB; McSorley SJ
PLoS One; 2020; 15(7):e0235518. PubMed ID: 32614928
[TBL] [Abstract][Full Text] [Related]
13. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
14. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.
Goods BA; Hernandez AL; Lowther DE; Lucca LE; Lerner BA; Gunel M; Raddassi K; Coric V; Hafler DA; Love JC
PLoS One; 2017; 12(9):e0181538. PubMed ID: 28880903
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
16. PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis.
Chiku VM; Silva KL; de Almeida BF; Venturin GL; Leal AA; de Martini CC; de Rezende Eugênio F; Dos Santos PS; de Lima VM
Immunobiology; 2016 Aug; 221(8):879-88. PubMed ID: 27016050
[TBL] [Abstract][Full Text] [Related]
17. PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.
Wu X; Zhang H; Xing Q; Cui J; Li J; Li Y; Tan Y; Wang S
Br J Cancer; 2014 Sep; 111(7):1391-9. PubMed ID: 25093496
[TBL] [Abstract][Full Text] [Related]
18. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
19. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.
Teigler JE; Zelinskyy G; Eller MA; Bolton DL; Marovich M; Gordon AD; Alrubayyi A; Alter G; Robb ML; Martin JN; Deeks SG; Michael NL; Dittmer U; Streeck H
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904197
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]